These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 11678429)

  • 1. Preliminary results of active specific immunization with modified tumor cell vaccine in glioblastoma multiforme.
    Schneider T; Gerhards R; Kirches E; Firsching R
    J Neurooncol; 2001 May; 53(1):39-46. PubMed ID: 11678429
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative active specific immunization in curatively resected colorectal cancer patients with a virus-modified autologous tumor cell vaccine.
    Lehner B; Schlag P; Liebrich W; Schirrmacher V
    Cancer Immunol Immunother; 1990; 32(3):173-8. PubMed ID: 2289211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newcastle disease virus-infected intact autologous tumor cell vaccine for adjuvant active specific immunotherapy of resected colorectal carcinoma.
    Ockert D; Schirrmacher V; Beck N; Stoelben E; Ahlert T; Flechtenmacher J; Hagmüller E; Buchcik R; Nagel M; Saeger HD
    Clin Cancer Res; 1996 Jan; 2(1):21-8. PubMed ID: 9816085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor vaccination of patients with glioblastoma multiforme: a pilot study to assess feasibility, safety, and clinical benefit.
    Steiner HH; Bonsanto MM; Beckhove P; Brysch M; Geletneky K; Ahmadi R; Schuele-Freyer R; Kremer P; Ranaie G; Matejic D; Bauer H; Kiessling M; Kunze S; Schirrmacher V; Herold-Mende C
    J Clin Oncol; 2004 Nov; 22(21):4272-81. PubMed ID: 15452186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/IIa trial of fractionated radiotherapy, temozolomide, and autologous formalin-fixed tumor vaccine for newly diagnosed glioblastoma.
    Ishikawa E; Muragaki Y; Yamamoto T; Maruyama T; Tsuboi K; Ikuta S; Hashimoto K; Uemae Y; Ishihara T; Matsuda M; Matsutani M; Karasawa K; Nakazato Y; Abe T; Ohno T; Matsumura A
    J Neurosurg; 2014 Sep; 121(3):543-53. PubMed ID: 24995786
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell vaccination combined with temozolomide retreatment: results of a phase I trial in patients with recurrent glioblastoma multiforme.
    Hunn MK; Bauer E; Wood CE; Gasser O; Dzhelali M; Ancelet LR; Mester B; Sharples KJ; Findlay MP; Hamilton DA; Hermans IF
    J Neurooncol; 2015 Jan; 121(2):319-29. PubMed ID: 25366363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients.
    Inogés S; Tejada S; de Cerio AL; Gállego Pérez-Larraya J; Espinós J; Idoate MA; Domínguez PD; de Eulate RG; Aristu J; Bendandi M; Pastor F; Alonso M; Andreu E; Cardoso FP; Valle RD
    J Transl Med; 2017 May; 15(1):104. PubMed ID: 28499389
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme.
    Izumoto S; Tsuboi A; Oka Y; Suzuki T; Hashiba T; Kagawa N; Hashimoto N; Maruno M; Elisseeva OA; Shirakata T; Kawakami M; Oji Y; Nishida S; Ohno S; Kawase I; Hatazawa J; Nakatsuka S; Aozasa K; Morita S; Sakamoto J; Sugiyama H; Yoshimine T
    J Neurosurg; 2008 May; 108(5):963-71. PubMed ID: 18447714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I/IIa trial of autologous formalin-fixed tumor vaccine concomitant with fractionated radiotherapy for newly diagnosed glioblastoma. Clinical article.
    Muragaki Y; Maruyama T; Iseki H; Tanaka M; Shinohara C; Takakura K; Tsuboi K; Yamamoto T; Matsumura A; Matsutani M; Karasawa K; Shimada K; Yamaguchi N; Nakazato Y; Sato K; Uemae Y; Ohno T; Okada Y; Hori T
    J Neurosurg; 2011 Aug; 115(2):248-55. PubMed ID: 21568657
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma.
    Yu JS; Liu G; Ying H; Yong WH; Black KL; Wheeler CJ
    Cancer Res; 2004 Jul; 64(14):4973-9. PubMed ID: 15256471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A pilot study of autologous cancer cell vaccination and cellular immunotherapy using anti-CD3 stimulated lymphocytes in patients with recurrent grade III/IV astrocytoma.
    Wood GW; Holladay FP; Turner T; Wang YY; Chiga M
    J Neurooncol; 2000 Jun; 48(2):113-20. PubMed ID: 11083074
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of recurrent glioblastoma: preliminary observations in a patient with a favorable response to therapy.
    Okada H; Lieberman FS; Edington HD; Witham TF; Wargo MJ; Cai Q; Elder EH; Whiteside TL; Schold SC; Pollack IF
    J Neurooncol; 2003; 64(1-2):13-20. PubMed ID: 12952282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Active immunotherapy using dendritic cells in the treatment of glioblastoma multiforme.
    Bregy A; Wong TM; Shah AH; Goldberg JM; Komotar RJ
    Cancer Treat Rev; 2013 Dec; 39(8):891-907. PubMed ID: 23790634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
    Heimberger AB; Sun W; Hussain SF; Dey M; Crutcher L; Aldape K; Gilbert M; Hassenbusch SJ; Sawaya R; Schmittling B; Archer GE; Mitchell DA; Bigner DD; Sampson JH
    Neuro Oncol; 2008 Feb; 10(1):98-103. PubMed ID: 18079360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine for aggressive brain tumors may prolong survival.
    Health News; 2004 Dec; 10(12):7. PubMed ID: 15645564
    [No Abstract]   [Full Text] [Related]  

  • 18. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma.
    Vik-Mo EO; Nyakas M; Mikkelsen BV; Moe MC; Due-Tønnesen P; Suso EM; Sæbøe-Larssen S; Sandberg C; Brinchmann JE; Helseth E; Rasmussen AM; Lote K; Aamdal S; Gaudernack G; Kvalheim G; Langmoen IA
    Cancer Immunol Immunother; 2013 Sep; 62(9):1499-509. PubMed ID: 23817721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preliminary report on tumor stem cell/B cell hybridoma vaccine for recurrent glioblastoma multiforme.
    Moviglia GA; Carrizo AG; Varela G; Gaeta CA; Paes de Lima A; Farina P; Molina H
    Hematol Oncol Stem Cell Ther; 2008; 1(1):3-13. PubMed ID: 20063522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma.
    Batich KA; Swartz AM; Sampson JH
    Expert Opin Biol Ther; 2015 Jan; 15(1):79-94. PubMed ID: 25327832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.